ArticleThe Kaohsiung journal of medical sciences2026
Composite Inflammatory Score for Predicting Progression-Free Survival in Metastatic Clear Cell Renal Cell Carcinoma Treated With First-Line Toripalimab Plus Axitinib.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Routine inflammatory and nutritional markers may help stratify progression risk in metastatic clear cell renal cell carcinoma during immunotherapy-based treatment. This single-center retrospective study included 237 patients who received first-line toripalimab plus axitinib therapy. Ten indices were natural-log transformed and standardized, and domain-based selection yielded a compact composite inflammatory score (COMP-IS), which was internally validated using 1000 full-pipeline bootstrap resamples. The primary endpoint was progression-free survival (PFS). During a median follow-up of 19.84 months for PFS, 124 events occurred. COMP-IS comprised the neutrophil-to-lymphocyte ratio, C-reactive protein-to-albumin ratio (CAR), and prognostic nutritional index. After adjusting for the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score, each standard deviation increase in COMP-IS was associated with shorter PFS (hazard ratio, 3.48; 95% confidence interval, 2.74-4.42). The apparent concordance index (C-index) for COMP-IS was 0.767, with a bootstrap-corrected C-index of 0.755, compared with corrected C-indices of 0.694 for CAR and 0.565 for the IMDC score. Adding IMDC to COMP-IS resulted in a corrected C-index of 0.756. In an exploratory post hoc comparison, the published Meet-URO risk groups had an apparent C-index of 0.593. COMP-IS demonstrated prognostic discrimination for PFS in this cohort; however, only internal validation was performed. Its clinical utility therefore remains uncertain, and independent external validation and prospective evaluation are needed before routine clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.